News In Brief: Sotyktu Phase III Win, Novo’s Alhemo Approval, Axsome Agitation Data, Pfizer Gives Back Sangamo Gene Therapy
Humanigen Indictment; WuXi Sells Cell And Gene Business
BMS's Sotyktu succeeded in two Phase III psoriatic arthritis trials, Novo's Alhemo (concizumab) was approved in the US for hemophilia A and B with inhibitors, Pfizer returned a hemophilia gene therapy to Sangamo ahead of US and EU filings, and more late December news.
